Efficacy and safety of nicotinamide in the management of hyperphosphatemia in pediatric patients on regular hemodialysis

详细信息    查看全文

• 作者：Radwa El Borolossy ; Lamia Mohamed El Wakeel ; Ihab El Hakim…
• 关键词：Pediatric patients ; Hemodialysis ; Nicotinamide ; Hyperphosphatemia ; Lipid profile
• 刊名：Pediatric Nephrology
• 出版年：2016
• 出版时间：February 2016
• 年：2016
• 卷：31
• 期：2
• 页码：289-296
• 全文大小：374 KB
• 参考文献：1.Six I, Maizel J, Barreto FC, Rangrez AY, Dupont S, Slama M (2012) Effects of phosphate on vascular function under normal conditions and influence of the uraemic state. Cardiovasc Res 96:130–139PubMed CrossRef
  2.Ganesh SK, Stack AG, Levin NW, Hulbert-Shearon T, Port FK (2001) Association of elevated serum PO4, Ca * PO4 product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients. J Am Soc Nephrol 12:2131–2139PubMed
  3.Block GA, Hulbert-Shearon TE, Levin NW, Port FK (1998) Association of serum phosphorus and calcium × phosphate product with mortality risk in chronic hemodialysis patients: a national study. Am J Kidney Dis 31:607–624PubMed CrossRef
  4.Mathew S, Tustison KS, Sugatani T, Chaudhary LR, Rifas L, Hruska KA (2008) The mechanism of phosphorus as a cardiovascular risk factor in CKD. J Am Soc Nephrol 19:1092–1105PubMed PubMedCentral CrossRef
  5.Levin A, Li YC (2005) Vitamin D and its analogues: do they protect against cardiovascular disease in patients with kidney disease. Kidney Int 68:1973–1981PubMed CrossRef
  6.Tonelli M, Pannu N, Manns B (2010) Oral phosphate binders in patients with kidney failure. N Engl J Med 362:1312–1324PubMed CrossRef
  7.Hutchison AJ, Smith CP, Brenchley PE (2011) Pharmacology, efficacy and safety of oral phosphate binders. Nat Rev Nephrol 7:578–589PubMed CrossRef
  8.Block GA, Wheeler DC, Persky MS, Kestenbaum B, Ketteler M, Spiegel DM (2012) Effects of phosphate binders in moderate CKD. J Am Soc Nephrol 23:1407–1415PubMed PubMedCentral CrossRef
  9.Manns B, Stevens L, Miskulin D, Owen WF Jr, Winkelmayer WC, Tonelli M (2004) A systematic review of sevelamer in ESRD and ananalysis of its potential economic impact in Canada and the United States. Kidney Int 66:1239–1247PubMed CrossRef
  10.Lenglet A, Liabeuf S, Guffroy P, Fournier A, Brazier M, Massy Z (2013) Use of nicotinamide to treat hyperphosphatemia in dialysis patients. Drugs R&D 13:165–173CrossRef
  11.O’Brien T, Silverberg J, Nguyen T (1992) Nicotinic acid induced toxicity associated with cytopenia and decrease level of thyroxin-binding globulin. Mayo Clin Proc 67:465–468PubMed CrossRef
  12.Katai K, Tanaka H, Tatsumi S (1999) Nicotinamide inhibits sodium-dependent phosphate cotransport activity in rat small intestine. Nephrol Dial Transplant 14:1195–1201PubMed CrossRef
  13.Kempson SA, Colon-Otero G, Ou SY, Turner ST, Dousa TP (1981) Possible role of nicotinamide adenine dinucleotide as an intracellular regulator of renal transport of phosphate in the rat. J Clin Invest 67:1347–1360PubMed PubMedCentral CrossRef
  14.Maccubbin D, Tipping D, Kuznetsova O, Hanlon WA, Bostom AG (2010) Hypophosphatemic effect of niacin in patients without renal failure: a randomized trial. Clin J Am Soc Nephrol 5:582–589PubMed PubMedCentral CrossRef
  15.Eto N, Miyata Y, Ohno H, Yamashita T (2005) Nicotinamide prevents the development of hyperphosphatemia by suppressing intestinal sodium-dependent phosphate transporter in rats with a renin-induced renal failure. Nephrol Dial Transplant 20:1378–1384PubMed CrossRef
  16.Takahashi Y, Tanaka A, Nakamura T, Fukuwatari T, Shibata K, Shimada N (2004) Nicotinamide suppress hyperphosphatemia in hemodialysis patients. Kidney Int 65:1099–1104PubMed CrossRef
  17.Sabbagh Y, O’Brien SP, Song W, Boulanger JH, Stockmann A, Arbeeny C (2009) Intestinal npt2b plays a major role in phosphate absorption and homeostasis. J Am Soc Nephrol 20:2348–2358PubMed PubMedCentral CrossRef
  18.Schiavi SC, Tang W, Bracken C, O’Brien SP, Song W, Boulanger J (2012) Npt2b deletion attenuates hyperphosphatemia associated with CKD. J Am Soc Nephrol 23:1691–1700PubMed PubMedCentral CrossRef
  19.Cheng SC, Young DO, Huang Y, Delmez JA, Coyne DW (2008) A randomized, double-blind, placebo-controlled trail of niacinamide for reduction of phosphorus in hemodialysis patients. Clin J Am Soc Nephrol 3:1131–1138PubMed PubMedCentral CrossRef
  20.Young DO, Cheng SC, Delmez JA, Coyne DW (2009) The effect of oral niacinamide on plasma phosphorus levels in peritoneal dialysis patients. Perit Dial Int 29:562–567PubMed
  21.Sampathkumar K, Selvam M, Sooraj YS, Gowthaman S, Ajeshkumar RN (2006) Extended release nicotinic acid: a novel oral agent for phosphate control. Int Urol Nephrol 38:171–174PubMed CrossRef
  22.Vasantha J, Soundararajan P, Vanitharani N, Kannan G, Thennarasu P, Neenu G (2011) Safety and efficacy of nicotinamide in the management of hyperphosphatemia in patients on hemodialysis. Indian J Nephrol 21:245–249PubMed PubMedCentral CrossRef
  23.Shahbazian H, Mohtashami A, Ghorbani A, Abbaspour MR, Belladi Musavi SS, Hayati F (2011) Oral nicotinamide reduces serum level of phosphorus, increase HDL, and induces thrombocytopenia in hemodialysis patients: a double-blind, randomized clinical trial. Nefrologia 31:58–65PubMed
  24.Muller D, Mehling H, Otto B, Otto B, Bergmann-Lips R, Luft F, Jordan J (2007) Niacin lowers serum phosphorus and increases HDL cholesterol in dialysis patients. Clin J Am Soc Nephrol 2:1249–1254PubMed CrossRef
  25.Knip M, Douek IF, Moore WP, Gillmor HA, McLean AEM, Bingley PJ (2000) Safety of high doses nicotinamide: a review. Diabetologia 43:1337–1345PubMed CrossRef
  26.Rottembourg J, Launay-Vacher V, Massard J (2005) Thrombocytopenia induced by nicotinamide in hemodialysis patients. Kidney Int 68:2911–2912PubMed CrossRef
  27.Gale E, Bingley P, Emmett C, Collier T (2004) European Nicotinamide Diabetes Intervention Trial (ENDIT) Group: a randomized controlled trial of intervention before the onset of type 1 diabetes. Lancet 363:925–931PubMed CrossRef
  28.Delanaye P, Weekers L, Krzesinski J (2006) Diarrhea induced by high doses of nicotinamide in dialysis patients. Kidney Int 69:1914PubMed CrossRef
  
• 作者单位：Radwa El Borolossy (1)
  Lamia Mohamed El Wakeel (1)
  Ihab El Hakim (2)
  Nagwa Sabri (1)
  
  1. Department of Clinical Pharmacy, Faculty of Pharmacy, Ain Shams University, 4 Street 292, New Maadi, Cairo, Egypt
  2. Department of Pediatrics, Faculty of Medicine, Ain Shams University, Cairo, Egypt
  
• 刊物类别：Medicine
• 刊物主题：Medicine & Public Health
  Pediatrics
  
• 出版者：Springer Berlin / Heidelberg
• ISSN：1432-198X

文摘

Background Hyperphosphatemia is a common problem in patients with end-stage renal disease (ESRD) who are on maintenance hemodialysis (HD) and contributes to the development of secondary hyperparathyroidism and cardiovascular complications. Nicotinamide (NAM) has been shown in some studies to inhibit intestinal and renal sodium/phosphorus co-transporters and reduce serum phosphorus levels. We have therefore evaluated the efficacy and safety of NAM as adjunctive therapy to calcium-based phosphate binders to control hyperphosphatemia in hemodialysis patients.